Tianjin Medical University Cancer Institute and Hospital
To evaluate the efficacy and safety of HAIC combined with Durvalumab, Tremelimumab and Bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma
Unrescetable Hepatocellular Carcinoma
HACK+Durvalumab+Tremlimumab+Bevacizumab
Phase 2
An open label, single-arm, single center, phase II study evaluating HAIC combined with Durvalumab, Tremelimumab and Bevacizumab as first-line therapy in unresectable hepatocellular carcinoma}}
Study Type : | Interventional |
Estimated Enrollment : | 30 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Hepatic Arterial Infusion Chemotherapy (HAIC) Plus Tremelimumab, Durvalumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma (HCC): a Single Center, Open Label, Single Arm, Phase II Trial |
Actual Study Start Date : | June 20, 2023 |
Estimated Primary Completion Date : | December 2024 |
Estimated Study Completion Date : | December 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: HACK+Durvalumab+Tremlimumab+Bevacizumab |
Drug: HAK+Durvalumab+Tremlimumab+Bevacizumab |
Ages Eligible for Study: | 18 Years to 85 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Tianjin Cancer Hospital Airport Hospital
Tianjin, Tianjin, China, 300308